Immunotherapy plus chemo and radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal cancer that has not spread to other parts of the body.
- You have not had any prior treatment for esophageal cancer, such as chemo or radiation.
- Your overall health is fairly good (able to do daily activities).
- Your heart, liver, kidneys, and blood counts are within normal ranges.
- You do not have active infections like hepatitis B, hepatitis C, or HIV, and no serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests different doses of radiation therapy combined with the immunotherapy drug sintilimab for people with locally advanced esophageal squamous cell carcinoma. The goal is to find the best radiation dose to improve treatment outcomes.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.